Compugen Ltd (CGEN) FinancialsCGENFinancialCompugen Ltd

Evaluating the bottom line, Compugen Ltd. maintains a gross margin of -3.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -339.62%, while the net margin is -269.25%. These profitability ratios, combined with a Return on Equity (ROE) of 50.64%, provide a clear picture of how effectively CGEN converts its operational activities into shareholder value.

In the context of the broader market, CGEN competes directly with industry leaders such as RNA and ALEC. With a market capitalization of $228.29M, it holds a leading position in the sector. When comparing efficiency, CGEN's gross margin of -3.54% stands against RNA's 100.00% and ALEC's 100.00%. Such benchmarking helps identify whether Compugen Ltd. is trading at a premium or discount relative to its financial performance.

Compugen has shown significant revenue growth in Q4 2025, reporting $67.33 million, a staggering 4480.3% year-over-year increase, indicating robust demand for its products. However, the company has faced challenges with profitability, as indicated by its GAAP EPS of -$0.08 in the most recent quarter, missing expectations by $0.01.